JP2019517597A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019517597A5 JP2019517597A5 JP2019517202A JP2019517202A JP2019517597A5 JP 2019517597 A5 JP2019517597 A5 JP 2019517597A5 JP 2019517202 A JP2019517202 A JP 2019517202A JP 2019517202 A JP2019517202 A JP 2019517202A JP 2019517597 A5 JP2019517597 A5 JP 2019517597A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- kit
- administered
- haf
- injury
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 33
- 208000004852 Lung Injury Diseases 0.000 claims description 12
- 206010069363 Traumatic lung injury Diseases 0.000 claims description 12
- 231100000515 lung injury Toxicity 0.000 claims description 12
- 230000006378 damage Effects 0.000 claims description 11
- 206010014561 Emphysema Diseases 0.000 claims description 10
- 239000000443 aerosol Substances 0.000 claims description 9
- 231100000331 toxic Toxicity 0.000 claims description 9
- 230000002588 toxic effect Effects 0.000 claims description 9
- 208000019693 Lung disease Diseases 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000006199 nebulizer Substances 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 6
- 208000027418 Wounds and injury Diseases 0.000 claims description 6
- 208000014674 injury Diseases 0.000 claims description 6
- 210000004072 lung Anatomy 0.000 claims description 6
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 5
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 5
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims description 5
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims description 5
- 229940024142 alpha 1-antitrypsin Drugs 0.000 claims description 5
- 208000006673 asthma Diseases 0.000 claims description 5
- 201000009267 bronchiectasis Diseases 0.000 claims description 5
- 206010006451 bronchitis Diseases 0.000 claims description 5
- 239000002575 chemical warfare agent Substances 0.000 claims description 5
- 208000007451 chronic bronchitis Diseases 0.000 claims description 5
- 230000001684 chronic effect Effects 0.000 claims description 5
- 229910052751 metal Inorganic materials 0.000 claims description 5
- 239000002184 metal Substances 0.000 claims description 5
- 150000002739 metals Chemical class 0.000 claims description 5
- 230000000414 obstructive effect Effects 0.000 claims description 5
- 239000000779 smoke Substances 0.000 claims description 5
- 239000008223 sterile water Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 206010003497 Asphyxia Diseases 0.000 claims description 4
- 241000283086 Equidae Species 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 239000000872 buffer Substances 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 239000000021 stimulant Substances 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 239000012895 dilution Substances 0.000 claims description 3
- 238000010790 dilution Methods 0.000 claims description 3
- PFWLFWPASULGAN-UHFFFAOYSA-N 7-methylxanthine Chemical compound N1C(=O)NC(=O)C2=C1N=CN2C PFWLFWPASULGAN-UHFFFAOYSA-N 0.000 claims description 2
- 241000282472 Canis lupus familiaris Species 0.000 claims description 2
- 241000282326 Felis catus Species 0.000 claims description 2
- 241000282412 Homo Species 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 231100000660 acute inhalation injury Toxicity 0.000 claims description 2
- 210000004381 amniotic fluid Anatomy 0.000 claims description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000000043 antiallergic agent Substances 0.000 claims description 2
- 239000004599 antimicrobial Substances 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 229940124630 bronchodilator Drugs 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 239000000032 diagnostic agent Substances 0.000 claims description 2
- 229940039227 diagnostic agent Drugs 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000037080 exercise endurance Effects 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 229940125721 immunosuppressive agent Drugs 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 230000000069 prophylactic effect Effects 0.000 claims description 2
- 230000002685 pulmonary effect Effects 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 238000000034 method Methods 0.000 description 22
- 206010069351 acute lung injury Diseases 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000002561 chemical irritant Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021137896A JP7371948B2 (ja) | 2016-06-13 | 2021-08-26 | 肺障害の処置のための羊水液剤 |
| JP2023112316A JP2023121866A (ja) | 2016-06-13 | 2023-07-07 | 肺障害の処置のための羊水液剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662349352P | 2016-06-13 | 2016-06-13 | |
| US62/349,352 | 2016-06-13 | ||
| US15/290,271 US20170354692A1 (en) | 2016-06-13 | 2016-10-11 | Amniotic fluid formulation for treatment of lung disorders |
| US15/290,271 | 2016-10-11 | ||
| PCT/US2017/037251 WO2017218535A1 (en) | 2016-06-13 | 2017-06-13 | Amniotic fluid formulation for treatment of lung disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021137896A Division JP7371948B2 (ja) | 2016-06-13 | 2021-08-26 | 肺障害の処置のための羊水液剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019517597A JP2019517597A (ja) | 2019-06-24 |
| JP2019517597A5 true JP2019517597A5 (enExample) | 2020-07-27 |
| JP7126268B2 JP7126268B2 (ja) | 2022-08-26 |
Family
ID=60572075
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019517202A Active JP7126268B2 (ja) | 2016-06-13 | 2017-06-13 | 肺障害の処置のための羊水液剤 |
| JP2021137896A Active JP7371948B2 (ja) | 2016-06-13 | 2021-08-26 | 肺障害の処置のための羊水液剤 |
| JP2023112316A Pending JP2023121866A (ja) | 2016-06-13 | 2023-07-07 | 肺障害の処置のための羊水液剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021137896A Active JP7371948B2 (ja) | 2016-06-13 | 2021-08-26 | 肺障害の処置のための羊水液剤 |
| JP2023112316A Pending JP2023121866A (ja) | 2016-06-13 | 2023-07-07 | 肺障害の処置のための羊水液剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20170354692A1 (enExample) |
| EP (1) | EP3468571B1 (enExample) |
| JP (3) | JP7126268B2 (enExample) |
| AU (1) | AU2017283482B2 (enExample) |
| CA (1) | CA3027489C (enExample) |
| ES (1) | ES2912075T3 (enExample) |
| WO (1) | WO2017218535A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2999420A1 (en) | 2005-09-27 | 2007-04-05 | Tissuetech, Inc. | Amniotic membrane preparations and purified compositions and methods of use |
| WO2012149486A1 (en) | 2011-04-28 | 2012-11-01 | Tissuetech, Inc. | Methods of modulating bone remodeling |
| KR102236805B1 (ko) | 2012-07-11 | 2021-04-05 | 티슈테크, 인코포레이티드 | Hc-ha/ptx3 복합체를 함유하는 조성물 및 이의 사용 방법 |
| WO2016111899A1 (en) * | 2015-01-05 | 2016-07-14 | Petrucci Gary M | Methods and materials for treating lung disorders |
| US20160243288A1 (en) | 2015-02-23 | 2016-08-25 | Tissuetech, Inc. | Apparatuses and methods for treating ophthalmic diseases and disorders |
| EP3297645A4 (en) | 2015-05-20 | 2018-12-12 | Tissuetech, Inc. | Compositions and methods for preventing the proliferation and epithelial-mesenchymal transition of epithelial cells |
| TW201733600A (zh) | 2016-01-29 | 2017-10-01 | 帝聖工業公司 | 胎兒扶持組織物及使用方法 |
| US20180096104A1 (en) * | 2016-10-05 | 2018-04-05 | MED Inc. | Disease management system |
| CN108434441A (zh) * | 2018-04-17 | 2018-08-24 | 哈尔滨博翱生物医药技术开发有限公司 | 新型成纤维细胞生长因子-21类似物在治疗弥漫性间质性肺脏疾病中的应用 |
| CN110812369A (zh) * | 2018-08-10 | 2020-02-21 | 浙江楚沅生物科技有限公司 | 用于治疗组织坏死或改善心脏功能的药物 |
| EP3858372A1 (en) * | 2020-01-31 | 2021-08-04 | AdVita Lifescience GmbH | Human anti-inflammatory peptides for the inhalatory treatment of inflammatory pulmonary diseases |
| WO2021152119A1 (en) * | 2020-01-31 | 2021-08-05 | Advita Lifescience Gmbh | Human anti-inflammatory peptides for the inhalatory treatment of inflammatory pulmonary diseases |
| CN113384300B (zh) * | 2020-03-11 | 2022-05-20 | 肖娓珠 | 一种妇产科羊水取样保存装置 |
| EP4125965A4 (en) * | 2020-04-03 | 2024-04-24 | University of Utah Research Foundation | METHOD OF TREATMENT OF LUNG DISEASE WITH CELLULAR AMNIOTIC FLUID |
| US12377121B2 (en) * | 2020-04-10 | 2025-08-05 | Zeo Scientifix, Inc. | Compositions comprising nanoparticles, method of making and uses thereof |
| WO2022118220A1 (en) * | 2020-12-02 | 2022-06-09 | Breathe Restore, Inc. | Compositions, devices, and methods for treating respiratory disorders |
| AU2022264378A1 (en) * | 2021-04-27 | 2023-10-12 | AVITA Medical Americas, LLC | Regenerative bioactive suspension derived from freshly disaggregated tissue and methods of use in clinical therapies |
| US12570949B2 (en) | 2022-12-27 | 2026-03-10 | AVITA Medical Americas, LLC | Systems and devices for wound therapy and related methods of use |
| JP2026500565A (ja) | 2022-12-27 | 2026-01-07 | アヴィータ・メディカル・アメリカズ，リミテッド・ライアビリティ・カンパニー | 再生上皮懸濁液の自動調製のためのシステムおよび関連する使用方法 |
| US11944742B1 (en) * | 2023-06-08 | 2024-04-02 | Microneb Tech Holdings, Inc. | Apparatus, methods, and systems for administering a medication to an animal |
| USD1112812S1 (en) | 2023-12-22 | 2026-02-10 | AVITA Medical Americas, LLC | Tissue processing cartridge |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1699479A (en) | 1928-04-27 | 1929-01-15 | Lilly Co Eli | Amniotic fluid and process of preparing it |
| US3752158A (en) | 1970-11-23 | 1973-08-14 | Snyder Manuf Co Inc | Apparatus and method for suprapubic drainage of the urinary bladder |
| US4308875A (en) | 1981-03-11 | 1982-01-05 | Universal Medical Instrument Corporation | Amniocentesis needle |
| US5436135A (en) | 1985-09-02 | 1995-07-25 | Pasteur Merieux Serums Et Vaccins | New preparation of placenta collagen, their extraction method and their applications |
| US5219576A (en) | 1988-06-30 | 1993-06-15 | Collagen Corporation | Collagen wound healing matrices and process for their production |
| US4977897A (en) | 1988-08-17 | 1990-12-18 | Robert Hurwitz | Amniocentesis needle with improved sonographic visibility |
| US5000192A (en) | 1990-01-02 | 1991-03-19 | Sealfon Andrew I | Prenatal specimen collection method |
| BR9609393A (pt) | 1995-06-07 | 1999-12-21 | Organogenesis Inc | Composição injetável de colágeno; segmentos de fibra de colágeno reconstituìdos. |
| JP2731833B2 (ja) | 1995-06-26 | 1998-03-25 | 大同ほくさん株式会社 | 海洋生物を原料とした代用皮膚 |
| US7044945B2 (en) | 2001-03-30 | 2006-05-16 | Sand Bruce J | Prevention of regression in thermal ciliary muscle tendinoplasty |
| EP1549328A4 (en) | 2002-09-18 | 2009-07-08 | Emiliano Ghinelli | USE OF A HUMAN SHEEP SKIN COMPOSITION FOR PROPHYLAXIS AND TREATMENT OF DISEASES AND STATES OF EYE AND SKIN |
| US20050079147A1 (en) | 2003-10-14 | 2005-04-14 | Bernard Delaey | Wound healing compositions and uses |
| US20080286378A1 (en) | 2005-02-22 | 2008-11-20 | Ashley Behrens | Use of Amniotic Fluid (Af) in Treating Ocular Disease and Injury |
| EP1712220A1 (en) * | 2005-04-15 | 2006-10-18 | PARI GmbH Spezialisten für effektive Inhalation | Pharmaceutical aerosol composition |
| EP1919500A2 (en) | 2005-07-13 | 2008-05-14 | Anthrogenesis Corporation | Treatment of leg ulcers using placenta derived collagen biofabric |
| WO2007146105A2 (en) | 2006-06-05 | 2007-12-21 | Cryo-Cell International, Inc. | Procurement, isolation and cryopreservation of fetal placental cells |
| US8071135B2 (en) | 2006-10-04 | 2011-12-06 | Anthrogenesis Corporation | Placental tissue compositions |
| NZ597223A (en) | 2006-10-06 | 2013-09-27 | Anthrogenesis Corp | Native (telopeptide) placental collagen compositions |
| US20090054350A1 (en) | 2007-08-23 | 2009-02-26 | Jean-Louis Tayot | Process for the sterile concentration of collagen preparations, and collagen preparations obtained |
| EP2197270B8 (en) | 2007-09-07 | 2020-03-04 | Surgical Biologics, LLC | Placental tissue grafts and improved methods of preparing and using the same |
| WO2009128076A2 (en) | 2008-04-18 | 2009-10-22 | Collplant Ltd. | Methods of generating and using procollagen |
| ES2532428T3 (es) | 2009-06-16 | 2015-03-26 | Baxter International Inc | Esponja hemostática |
| US20120010727A1 (en) | 2010-07-06 | 2012-01-12 | AFcell Medical | Amnion and chorion constructs and uses thereof in sport injury surgeries |
| WO2014072468A1 (en) * | 2012-11-09 | 2014-05-15 | Velin-Pharma A/S | Compositions for pulmonary delivery |
| US20140336600A1 (en) | 2013-05-10 | 2014-11-13 | Carl Randall Harrell | Method for Obtaining Sterile Human Amniotic Fluid and Uses Thereof |
| US10485521B2 (en) * | 2013-05-10 | 2019-11-26 | MAM Holdings of West Florida, L.L.C. | Method for obtaining sterile human amniotic fluid and uses thereof |
| WO2015134936A1 (en) | 2014-03-06 | 2015-09-11 | Amnio Technology Llc | Amnion derived therapeutic compositions and methods of use |
| US9132156B1 (en) * | 2014-06-15 | 2015-09-15 | Amnio Technology Llc | Acellular amnion derived therapeutic compositions |
| WO2015134946A1 (en) * | 2014-03-06 | 2015-09-11 | Amnio Technology Llc | Amnion derived therapeutic compositions and methods of use |
| KR20160001267A (ko) | 2014-06-27 | 2016-01-06 | 삼성전자주식회사 | 커넥터 플러그 및 커넥터 소켓 |
| US10517903B2 (en) | 2015-09-14 | 2019-12-31 | Amnio Technology Llc | Amnion derived therapeutic composition and process of making same |
| US9579350B1 (en) * | 2016-02-25 | 2017-02-28 | MAM Holdings of West Florida, L.L.C. | Human amniotic fluid preparation having long-term stability |
| AU2017237093B2 (en) * | 2016-03-23 | 2022-12-01 | Mimedx Group, Inc. | Compositions and methods of treatment with amniotic fluid |
-
2016
- 2016-10-11 US US15/290,271 patent/US20170354692A1/en not_active Abandoned
-
2017
- 2017-06-13 EP EP17737937.7A patent/EP3468571B1/en active Active
- 2017-06-13 JP JP2019517202A patent/JP7126268B2/ja active Active
- 2017-06-13 CA CA3027489A patent/CA3027489C/en active Active
- 2017-06-13 WO PCT/US2017/037251 patent/WO2017218535A1/en not_active Ceased
- 2017-06-13 AU AU2017283482A patent/AU2017283482B2/en not_active Ceased
- 2017-06-13 ES ES17737937T patent/ES2912075T3/es active Active
-
2018
- 2018-01-22 US US15/876,988 patent/US11491189B2/en active Active
-
2021
- 2021-08-26 JP JP2021137896A patent/JP7371948B2/ja active Active
-
2022
- 2022-09-19 US US17/933,374 patent/US20230021477A1/en active Pending
-
2023
- 2023-07-07 JP JP2023112316A patent/JP2023121866A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019517597A5 (enExample) | ||
| Lavorini et al. | Dilemmas, confusion, and misconceptions related to small airways directed therapy | |
| NZ585856A (en) | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease | |
| CA2474479A1 (en) | Composition for inhalation | |
| NZ585857A (en) | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease | |
| US12171788B2 (en) | Methods and materials for treating lung disorders | |
| RU2006132038A (ru) | Комбинация (варианты) и фармацевтический препарат для лечения заболеваний дыхательных путей | |
| CN101244063A (zh) | 包含高效长效β2－激动剂和其它活性成分的药物组合物 | |
| JP2007520508A5 (enExample) | ||
| RU2006132036A (ru) | Комбинация и фармацевтический препарат для лечения аллергий и заболеваний дыхательных путей | |
| Popov et al. | In vitro and in vivo evaluation of the efficacy and safety of powder hydroxypropylmethylcellulose as nasal mucosal barrier | |
| JP2008533072A5 (enExample) | ||
| CN106488770A (zh) | 用于治疗copd的福莫特罗和布地奈德的组合 | |
| GB2430623A (en) | Medicaments for treating chronic respiratory disease | |
| JP5501451B2 (ja) | 咳の治療のためのテオブロミン | |
| RU2010120806A (ru) | Композиции для ингаляции, содержащие кислоту монтелукаст и ингибитор pde-4 или ингаляционный кортикостероид | |
| JP2011500731A5 (enExample) | ||
| EP3393517B1 (en) | Acetylsalicylic acid for use in the treatment of moderate to severe influenza | |
| JP2020019721A (ja) | 閉塞性気道疾患の抑制又は軽減のための組成物 | |
| EP2826479B1 (en) | Ameliorating agent for chronic obstructive pulmonary disease | |
| Herxheimer | The protective action of antihistaminic and sympathomimetic aerosols in anaphylactic microshock of the guinea-pig | |
| Castro et al. | Asthma intervention research 2 (AIR2) trial | |
| CN106727504A (zh) | 辛伐他汀在制备预防高分压氧导致的肺型氧中毒的药物中的应用 | |
| TW202310855A (zh) | 使用一氧化二氮或任何吸入性麻醉劑治療covid-19及其他病毒感染、細菌感染、損傷、急性呼吸窘迫症候群或導致p物質水平急性升高引起細胞激素系統之病理性活化之病症 | |
| US20220054509A1 (en) | Methods of treatment for disease from coronavirus exposure |